These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 23548645)

  • 1. Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes.
    Tsu LV; Dager WE
    Ann Pharmacother; 2013 Apr; 47(4):573-7. PubMed ID: 23548645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
    Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
    Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
    Davis EM; Packard KA; Knezevich JT; Campbell JA
    Pharmacotherapy; 2011 Oct; 31(10):975-1016. PubMed ID: 21950643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticoagulants and dual antiplatelet therapy combined, a challenge to our intelligence].
    Morais J
    Rev Port Cardiol; 2012 Apr; 31 Suppl 1():38-44. PubMed ID: 22541034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban (Xarelto) for acute coronary syndrome.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in acute coronary syndrome.
    Ahrens I; Bode C
    Semin Hematol; 2014 Apr; 51(2):147-51. PubMed ID: 24861799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticoagulant therapy in secondary prevention of coronary events].
    Bultas J
    Vnitr Lek; 2014 Dec; 60(12):1023-32. PubMed ID: 25692828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials.
    Paikin JS; Wright DS; Eikelboom JW
    Blood Rev; 2011 May; 25(3):123-9. PubMed ID: 21354678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute coronary syndrome: Is there a place for direct oral anticoagulants?].
    Cayla G; Leclercq F; Schmutz L; Cornillet L; Ledermann B; Messner P; Lattuca B
    Presse Med; 2016 Oct; 45(10):919-925. PubMed ID: 27597298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.